Matches in SemOpenAlex for { <https://semopenalex.org/work/W2102804556> ?p ?o ?g. }
Showing items 1 to 95 of
95
with 100 items per page.
- W2102804556 endingPage "274" @default.
- W2102804556 startingPage "271" @default.
- W2102804556 abstract "Objectives Pemetrexed-cisplatin is the only FDA-approved regimen for malignant pleural mesothelioma (MPM), and the impact on survival is modest. No drugs have been shown to improve survival as second-line therapy, yet vinorelbine and gemcitabine are prescribed based on the results of small phase II trials. To augment the existing limited data, we examined our institutional experience with vinorelbine and gemcitabine in patients with previously treated MPM. Materials and methods We reviewed charts of patients with MPM treated with vinorelbine and/or gemcitabine as second- or third-line therapy between 2003 and 2010. Toxicity was graded according to the Common Terminology Criteria for Adverse Events Version 4.0. CT scans were reviewed with a reference radiologist according to modified RECIST criteria. Results Sixty patients were identified: 33 treated with vinorelbine, 15 gemcitabine, and 12 both agents. Eighty-three percent initially received pemetrexed-platinum. Toxicity was substantial: 46% experienced at least one episode of grade 3–4 toxicity. Of 56 patients evaluable radiologically, there was 1 partial response (gemcitabine) giving a response rate of 2% (95% CI: 0–10%). Forty-six percent had stable disease. Median progression free survival was 1.7 months for vinorelbine and 1.6 months for gemcitabine. Median overall survival was 5.4 and 4.9 months, respectively. Conclusions Response to second- or third-line vinorelbine or gemcitabine is rare. The high rate of stable disease warrants the continued use of these agents in this setting, though the impact on survival is questionable. These data justify the choice of placebo control arms in randomized trials of novel agents in previously treated patients." @default.
- W2102804556 created "2016-06-24" @default.
- W2102804556 creator A5008675566 @default.
- W2102804556 creator A5012346270 @default.
- W2102804556 creator A5014084163 @default.
- W2102804556 creator A5050489521 @default.
- W2102804556 creator A5060393514 @default.
- W2102804556 creator A5064351325 @default.
- W2102804556 date "2014-06-01" @default.
- W2102804556 modified "2023-10-05" @default.
- W2102804556 title "Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma" @default.
- W2102804556 cites W1987213291 @default.
- W2102804556 cites W1987724930 @default.
- W2102804556 cites W1996124858 @default.
- W2102804556 cites W2010146492 @default.
- W2102804556 cites W2034357535 @default.
- W2102804556 cites W2050014528 @default.
- W2102804556 cites W2050291724 @default.
- W2102804556 cites W2094586578 @default.
- W2102804556 cites W2100576484 @default.
- W2102804556 cites W2102627969 @default.
- W2102804556 cites W2151439313 @default.
- W2102804556 cites W2163456861 @default.
- W2102804556 cites W4245520901 @default.
- W2102804556 doi "https://doi.org/10.1016/j.lungcan.2014.03.006" @default.
- W2102804556 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4343315" @default.
- W2102804556 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24690410" @default.
- W2102804556 hasPublicationYear "2014" @default.
- W2102804556 type Work @default.
- W2102804556 sameAs 2102804556 @default.
- W2102804556 citedByCount "89" @default.
- W2102804556 countsByYear W21028045562014 @default.
- W2102804556 countsByYear W21028045562015 @default.
- W2102804556 countsByYear W21028045562016 @default.
- W2102804556 countsByYear W21028045562017 @default.
- W2102804556 countsByYear W21028045562018 @default.
- W2102804556 countsByYear W21028045562019 @default.
- W2102804556 countsByYear W21028045562020 @default.
- W2102804556 countsByYear W21028045562021 @default.
- W2102804556 countsByYear W21028045562022 @default.
- W2102804556 countsByYear W21028045562023 @default.
- W2102804556 crossrefType "journal-article" @default.
- W2102804556 hasAuthorship W2102804556A5008675566 @default.
- W2102804556 hasAuthorship W2102804556A5012346270 @default.
- W2102804556 hasAuthorship W2102804556A5014084163 @default.
- W2102804556 hasAuthorship W2102804556A5050489521 @default.
- W2102804556 hasAuthorship W2102804556A5060393514 @default.
- W2102804556 hasAuthorship W2102804556A5064351325 @default.
- W2102804556 hasBestOaLocation W21028045562 @default.
- W2102804556 hasConcept C126322002 @default.
- W2102804556 hasConcept C141071460 @default.
- W2102804556 hasConcept C143998085 @default.
- W2102804556 hasConcept C2776694085 @default.
- W2102804556 hasConcept C2777240266 @default.
- W2102804556 hasConcept C2777793932 @default.
- W2102804556 hasConcept C2778239845 @default.
- W2102804556 hasConcept C2780258809 @default.
- W2102804556 hasConcept C2780350996 @default.
- W2102804556 hasConcept C2781413609 @default.
- W2102804556 hasConcept C71924100 @default.
- W2102804556 hasConceptScore W2102804556C126322002 @default.
- W2102804556 hasConceptScore W2102804556C141071460 @default.
- W2102804556 hasConceptScore W2102804556C143998085 @default.
- W2102804556 hasConceptScore W2102804556C2776694085 @default.
- W2102804556 hasConceptScore W2102804556C2777240266 @default.
- W2102804556 hasConceptScore W2102804556C2777793932 @default.
- W2102804556 hasConceptScore W2102804556C2778239845 @default.
- W2102804556 hasConceptScore W2102804556C2780258809 @default.
- W2102804556 hasConceptScore W2102804556C2780350996 @default.
- W2102804556 hasConceptScore W2102804556C2781413609 @default.
- W2102804556 hasConceptScore W2102804556C71924100 @default.
- W2102804556 hasIssue "3" @default.
- W2102804556 hasLocation W21028045561 @default.
- W2102804556 hasLocation W21028045562 @default.
- W2102804556 hasLocation W21028045563 @default.
- W2102804556 hasLocation W21028045564 @default.
- W2102804556 hasOpenAccess W2102804556 @default.
- W2102804556 hasPrimaryLocation W21028045561 @default.
- W2102804556 hasRelatedWork W1980170271 @default.
- W2102804556 hasRelatedWork W2057160446 @default.
- W2102804556 hasRelatedWork W2073104701 @default.
- W2102804556 hasRelatedWork W2085142786 @default.
- W2102804556 hasRelatedWork W2351358978 @default.
- W2102804556 hasRelatedWork W2404692521 @default.
- W2102804556 hasRelatedWork W2439707001 @default.
- W2102804556 hasRelatedWork W2468005262 @default.
- W2102804556 hasRelatedWork W2621339296 @default.
- W2102804556 hasRelatedWork W3127521146 @default.
- W2102804556 hasVolume "84" @default.
- W2102804556 isParatext "false" @default.
- W2102804556 isRetracted "false" @default.
- W2102804556 magId "2102804556" @default.
- W2102804556 workType "article" @default.